| pubmed-article:15389912 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15389912 | lifeskim:mentions | umls-concept:C1367654 | lld:lifeskim |
| pubmed-article:15389912 | lifeskim:mentions | umls-concept:C0679246 | lld:lifeskim |
| pubmed-article:15389912 | lifeskim:mentions | umls-concept:C1517677 | lld:lifeskim |
| pubmed-article:15389912 | lifeskim:mentions | umls-concept:C1136085 | lld:lifeskim |
| pubmed-article:15389912 | lifeskim:mentions | umls-concept:C1517067 | lld:lifeskim |
| pubmed-article:15389912 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:15389912 | pubmed:dateCreated | 2004-9-29 | lld:pubmed |
| pubmed-article:15389912 | pubmed:abstractText | Monoclonal gammopathy is a well-recognized occurrence in splenic marginal zone lymphoma (MZL); however, its prevalence has never been reported in extranodal MZL (ENMZL). We present results of a retrospective analysis of 26 patients with newly diagnosed as well as previously treated ENMZL. Monoclonal gammopathy was detected in 7 out of 26 (27%) patients. All patients with a monoclonal gammopathy had stage IV disease, and most of them had involvement of lymph nodes and/or bone marrow (n = 6). Only 1 out of 7 patients with a monoclonal spike had stage IV disease diagnosed based on multifocal mucosal involvement. There was also a strong correlation between the involvement of bone marrow and the presence of a monoclonal spike (Fisher's exact test, P = 0.0007). Prevalence of monoclonal gammopathy is higher than previously recognized and indicates advanced disease. However, the prognostic significance of the presence of monoclonal gammopathy in this population is unknown. | lld:pubmed |
| pubmed-article:15389912 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15389912 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15389912 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15389912 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15389912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15389912 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15389912 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:15389912 | pubmed:issn | 0361-8609 | lld:pubmed |
| pubmed-article:15389912 | pubmed:author | pubmed-author:CohenPhilipP | lld:pubmed |
| pubmed-article:15389912 | pubmed:author | pubmed-author:ChesonBruce... | lld:pubmed |
| pubmed-article:15389912 | pubmed:author | pubmed-author:KesslerCraig... | lld:pubmed |
| pubmed-article:15389912 | pubmed:author | pubmed-author:MavromatisBla... | lld:pubmed |
| pubmed-article:15389912 | pubmed:author | pubmed-author:OzdemirliMeti... | lld:pubmed |
| pubmed-article:15389912 | pubmed:author | pubmed-author:AsatianiEkath... | lld:pubmed |
| pubmed-article:15389912 | pubmed:copyrightInfo | Copyright 2004 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:15389912 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15389912 | pubmed:volume | 77 | lld:pubmed |
| pubmed-article:15389912 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15389912 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15389912 | pubmed:pagination | 144-6 | lld:pubmed |
| pubmed-article:15389912 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15389912 | pubmed:meshHeading | pubmed-meshheading:15389912... | lld:pubmed |
| pubmed-article:15389912 | pubmed:meshHeading | pubmed-meshheading:15389912... | lld:pubmed |
| pubmed-article:15389912 | pubmed:meshHeading | pubmed-meshheading:15389912... | lld:pubmed |
| pubmed-article:15389912 | pubmed:meshHeading | pubmed-meshheading:15389912... | lld:pubmed |
| pubmed-article:15389912 | pubmed:meshHeading | pubmed-meshheading:15389912... | lld:pubmed |
| pubmed-article:15389912 | pubmed:meshHeading | pubmed-meshheading:15389912... | lld:pubmed |
| pubmed-article:15389912 | pubmed:meshHeading | pubmed-meshheading:15389912... | lld:pubmed |
| pubmed-article:15389912 | pubmed:meshHeading | pubmed-meshheading:15389912... | lld:pubmed |
| pubmed-article:15389912 | pubmed:meshHeading | pubmed-meshheading:15389912... | lld:pubmed |
| pubmed-article:15389912 | pubmed:meshHeading | pubmed-meshheading:15389912... | lld:pubmed |
| pubmed-article:15389912 | pubmed:meshHeading | pubmed-meshheading:15389912... | lld:pubmed |
| pubmed-article:15389912 | pubmed:meshHeading | pubmed-meshheading:15389912... | lld:pubmed |
| pubmed-article:15389912 | pubmed:meshHeading | pubmed-meshheading:15389912... | lld:pubmed |
| pubmed-article:15389912 | pubmed:meshHeading | pubmed-meshheading:15389912... | lld:pubmed |
| pubmed-article:15389912 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15389912 | pubmed:articleTitle | Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement. | lld:pubmed |
| pubmed-article:15389912 | pubmed:affiliation | Georgetown University Hospital, Departments of Oncology and Medicine, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA. ea26@georgetown.edu | lld:pubmed |
| pubmed-article:15389912 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15389912 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15389912 | lld:pubmed |
